Epstein-Barr Virus (EBV) DNA, PCR (Real-Time)

The Epstein-Barr Virus (EBV) DNA, PCR (Real-Time) assay, also referred to as EBV DNA PCR or EBV PCR, is used to demonstrate the presence of EBV DNA when serologic markers have not yet appeared, enabling early diagnosis of infectious mononucleosis. The test also contributes to the differential evaluation of herpesvirus-related upper airway disease, including tonsillopharyngitis. In immunocompromised populations—such as transplant recipients and individuals receiving intensive immunosuppression—this assay supports assessment of EBV reactivation. Detection of EBV DNA in these settings informs clinical correlation for EBV-related disease risk and activity.

Epstein-Barr virus, a member of the Herpesviridae family, predominantly targets B lymphocytes but can also involve T lymphocytes and epithelial cells. Transmission most often occurs through respiratory secretions. Primary infection is commonly acquired in childhood and is frequently asymptomatic or minimally symptomatic. In adolescents and adults, it more often manifests as infectious mononucleosis characterized by fever, malaise, lymphadenopathy, and tonsillopharyngitis, with possible hepatosplenomegaly. Complications of EBV infection may include hepatitis, pneumonia, hemolytic anemia, thrombocytopenia, aplastic anemia, splenic rupture, myocarditis, and neurologic syndromes such as Guillain–Barré syndrome, encephalitis, and meningitis. The virus establishes lifelong latency in memory B cells and epithelial cells. Reactivation during immunosuppression (eg, HIV infection or post-transplant therapy) is associated with lymphoproliferative disorders and nasopharyngeal carcinoma, and may present with recurrent mononucleosis-like illness. Polymerase chain reaction identifies EBV DNA by target amplification. False-negative results can occur when specimen collection is inadequate, handling is suboptimal, inhibitory fixatives are present, or the EBV DNA burden is below the analytical sensitivity of the assay.